MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income Takes $9.04 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 251,659 shares of the company’s stock, valued at approximately $9,035,000. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income owned about 0.52% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Lazard Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $42,000. Advisor Group Holdings Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 314.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock valued at $54,000 after purchasing an additional 1,753 shares during the period. FinTrust Capital Advisors LLC acquired a new stake in Amphastar Pharmaceuticals during the 1st quarter worth $143,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Amphastar Pharmaceuticals by 89.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,710 shares of the company’s stock worth $156,000 after buying an additional 3,161 shares during the period. Finally, Strs Ohio raised its stake in Amphastar Pharmaceuticals by 12.8% during the 1st quarter. Strs Ohio now owns 5,300 shares of the company’s stock worth $190,000 after buying an additional 600 shares during the period. 59.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AMPH has been the subject of several analyst reports. Northland Securities raised their price objective on Amphastar Pharmaceuticals from $33.00 to $43.00 in a report on Monday, April 11th. Capital One Financial started coverage on Amphastar Pharmaceuticals in a report on Friday, July 29th. They issued an “overweight” rating and a $44.00 price objective for the company. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH traded down $0.20 during midday trading on Friday, reaching $36.76. 336,381 shares of the company were exchanged, compared to its average volume of 274,202. The stock’s 50-day moving average price is $35.28 and its 200-day moving average price is $33.41. The stock has a market cap of $1.79 billion, a P/E ratio of 22.83 and a beta of 0.67. Amphastar Pharmaceuticals, Inc. has a one year low of $17.56 and a one year high of $44.46. The company has a quick ratio of 2.35, a current ratio of 3.19 and a debt-to-equity ratio of 0.16.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Rating) last posted its earnings results on Monday, May 9th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. Amphastar Pharmaceuticals had a net margin of 17.87% and a return on equity of 17.35%. The firm had revenue of $120.37 million for the quarter, compared to analysts’ expectations of $110.60 million. During the same quarter in the previous year, the firm posted $0.27 earnings per share. On average, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jack Y. Zhang sold 67,046 shares of the company’s stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $34.14, for a total value of $2,288,950.44. Following the sale, the chief executive officer now owns 2,156,523 shares in the company, valued at approximately $73,623,695.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Amphastar Pharmaceuticals news, Director Diane G. Gerst sold 1,520 shares of the company’s stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $37.23, for a total value of $56,589.60. Following the completion of the sale, the director now directly owns 12,842 shares of the company’s stock, valued at approximately $478,107.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack Y. Zhang sold 67,046 shares of the company’s stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $34.14, for a total transaction of $2,288,950.44. Following the completion of the sale, the chief executive officer now directly owns 2,156,523 shares of the company’s stock, valued at $73,623,695.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 148,641 shares of company stock worth $5,187,590. Company insiders own 27.80% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

(Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Further Reading

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.